Dr. Michael Har-Noy Describes the Priming Phase of his CRCL-AlloVaxTM Study (Part 2)

DENVER, CO, April 10, 2014 (Press-News.org) Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., a biotechnology company in Israel, says that to activate the vaccine-like properties of AlloStim , the AlloStim cells are given to the patient via intradermal (just under the skin) injection. This intradermal injection creates a 'bubble' under the skin similar to that caused by a purified protein derivative (PPD) test for tuberculosis.

Dr. Michael Har-Noy says that because the AlloStim cells are foreign to the patient, they will be rejected by the patient's immune system. Specialized dendritic cells (Langerhans cells) that reside in large numbers in the patient's skin will migrate to the AlloStimTM administration site to engulf and process the foreign protein material. The cytokines produced by the microbead-activated AlloStim cells before the rejection process cause the dendritic cells to develop into Type 1 dendritic cells (DC1) that produce high levels of interleukin 12 (IL-12). These DC1 cells are responsible for strengthening the patient's type 1 T-helper (Th1) immune response. Dr. Michael Har-Noy says that in cancer patients, cytokines (such as interleukin 4, interleukin 10, and Transforming Growth Factor-beta) produced by the malignant cells cause dendritic cells to mature into Type 2 dendritic cells (DC2), which channel the patient's immune response to type 2 T-helper (Th2) cells. Dr. Michael Har-Noy indicates that this is why patients with malignancies often lack an effective Th1 immune response and exhibit an increase in immunologically impotentTh2cell activity.

Dr. Michael Har-Noy goes on to say that the DC1 cells created after the AlloStimTM injection will migrate to the draining lymph nodes where they will promote the production and release of foreign (alloantigen)-specific Th1 cells and cytotoxic T-lymphocyte (CTL) killer T-cells into the circulation. These additional Th1 cells will serve to shift the immune balance away from a Th2 environment and towards a Th1 dominant response.

Because it can take as many as three days for a patient's Langerhans cells to migrate to the rejection site, Dr. Michael Har-Noy says that three days after the initial intradermal AlloStimTM injection (day seven of the protocol), a second AlloStim intradermal injection is given to the patient in the exact same location as the first dose. This additional AlloStimTM injection assures that inflammatory cytokines will be present at the time the Langerhans cells begin processing the foreign antigens. Dr. Michael Har-Noy adds that this will assure that these cells mature to DC1 cells. Additionally, multiple exposures to the foreign antigens in the AlloStim will help the patient's immune system create memory Th1 and CTL cells.

Dr. Michael Har-Noy says that the double intradermal dosing of AlloStim in the same location effectively immunizes the patient against the foreign AlloStim antigens. The activated AlloStim cells drives the maturation of resident Langerhans cells into DC1 cells, then facilitates production of Th1 and CTL cells in the patient's lymphatic system. Dr. Michael Har-Noy adds that the multiple AlloStim injections promote memory cell formation. The final result of this priming process is an increase in the number of Th1 and CTL memory cells in the patient's circulation, which helps to correct the pathologic Th2-dominated immune environment usually present in patients with malignancies.

Dr. Michael Har-Noy concludes that after the above priming process the patient's immune system is ready to respond vigorously to any re-exposure to the foreign proteins of malignant cells.

For more information on Dr. Michael Har-Noy's on-going Phase I/II trials and Compassionate Use programs, please visit www.immunocare.net.

About: Dr. Michael Har-Noy is the founder and CEO of Immunovative Therapies, Ltd. a biotechnology company in Israel. Dr. Michael Har-Noy develops proprietary biologic drugs aimed at treating a wide variety of cancers.